Blue Ox Healthcare Partners

Blue Ox Healthcare Partners is a private equity investment firm established in 2009 and based in New York. It specializes in providing capital to growth-stage companies within the healthcare sector, specifically focusing on healthcare services, health technology, and life sciences. The firm targets middle-market businesses that are driving innovation and transformation towards individualized and value-based care. With a deep understanding of the healthcare industry, Blue Ox leverages its investment and operational expertise to support the long-term growth of its portfolio companies.

Oded Levy

Managing Partner

John Neczesny

Managing Partner, COO and Member of Investment Committee

Alex Rogers

Principal

9 past transactions

Epic Sciences

Series G in 2023
Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

Gemelli Biotech

Series A in 2022
Gemelli Biotech is a North Carolina-based biotechnology company founded in 2018 that focuses on the human microbiome and diagnostics for irritable bowel syndrome (IBS). The company develops medical devices and diagnostic tools, including blood tests to measure specific antibodies elevated in patients with post-infectious IBS and a breath test system to identify small intestinal bacterial overgrowth. These innovations aim to enhance diagnostic protocols for various IBS types, including diarrhea-predominant and mixed-type. Gemelli Biotech is committed to advancing healthcare by fostering the discovery of new diagnostics and therapeutics for the microbiome in a responsible and socially conscious manner, ultimately striving to improve global health outcomes.

Epic Sciences

Series F in 2022
Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

Sera Prognostics

Series E in 2021
Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, focused on developing diagnostic tests that assess a woman's individual risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other pregnancy-related complications. Founded in 2008, Sera aims to improve maternal and neonatal health while addressing the significant economic and healthcare burdens associated with premature birth. The company's proprietary proteomics and bioinformatics platform underpins its pipeline of innovative diagnostic tests, including the PreTRM® Test, which provides physicians with critical information to identify women at higher risk for spontaneous premature delivery. By enabling earlier proactive interventions, Sera seeks to enhance pregnancy care and reduce healthcare delivery costs.

Sera Prognostics

Series D in 2019
Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, focused on developing diagnostic tests that assess a woman's individual risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other pregnancy-related complications. Founded in 2008, Sera aims to improve maternal and neonatal health while addressing the significant economic and healthcare burdens associated with premature birth. The company's proprietary proteomics and bioinformatics platform underpins its pipeline of innovative diagnostic tests, including the PreTRM® Test, which provides physicians with critical information to identify women at higher risk for spontaneous premature delivery. By enabling earlier proactive interventions, Sera seeks to enhance pregnancy care and reduce healthcare delivery costs.

Epic Sciences

Series E in 2018
Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through innovative testing methods. The company specializes in developing highly sensitive tests to identify and characterize circulating tumor cells (CTCs) from minimally invasive blood samples. Its advanced platform can profile single-cell phenotypes and genotypes, assessing various characteristics such as biomarker expression levels and morphologic traits. Epic Sciences also offers the Oncotype DX AR-V7 Nucleus Detect test for patients with metastatic castration-resistant prostate cancer, along with biopharmaceutical solutions. The company collaborates with biotechnology and pharmaceutical partners, major cancer centers, and research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and provide real-time biopsy material for cancer treatment guidance. Founded in 2008, Epic Sciences is committed to facilitating quick and effective cancer diagnostics.

RX Solutions

Private Equity Round in 2018
RX Solutions, LLC is a company based in Boynton Beach, Florida, that specializes in medical prescription assistance services aimed at helping lower-income individuals access fixed and reduced cost prescription drugs. The organization identifies specific Prescription Assistance Programs (PAPs) tailored to the medication needs of consumers, guiding them through the entire process to secure necessary subsidies and medications. RX Solutions offers assistance for various medications, including Trulicity, Victoza, and ProAir, ensuring that clients receive the support they need to afford their prescriptions.

Infinity Behavioral Health Services

Private Equity Round in 2015
Infinity Behavioral Health Services, LLC is a Fort Lauderdale, Florida-based company that specializes in providing comprehensive billing and consulting services for behavioral health facilities engaged in substance abuse and mental health treatment. Established in 2011, the company offers a range of solutions, including electronic claim submissions, claim scrubbing software, and detailed billing with appropriate coding. It also manages follow-up on unpaid claims, negotiates single-case agreements and in-network contracts, and provides customized reporting services. Additionally, Infinity delivers consulting on various operational aspects, such as admissions processes, documentation templates, and care guidelines. The company's expertise extends to assisting clients with clinical documentation, program scheduling, and eligibility verification, ensuring that behavioral health providers can focus on patient care while maximizing their insurance revenue.

PatientMatters

Private Equity Round in 2015
PatientMatters offers a comprehensive patient receivables solution aimed at enhancing the financial outcomes for healthcare providers while improving the patient experience. The company focuses on addressing key areas of cash leakage, including pre-registration, emergency room collections, and bad-debt management. Through its platform, PatientMatters integrates patient registration, bill estimation, and financial services, employing intelligent workflows to streamline processes. This approach not only helps hospitals increase cash collections and reduce bad debt but also fosters better relationships between patients and healthcare providers. By utilizing a unique data set, PatientMatters educates and engages both hospital staff and patients, aligning incentives to create a more efficient and effective financial ecosystem in healthcare.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.